AP 24534

[Guest guest]

This is a report dated May 22. 2008 from NIH:

" The start of patient enrollment in this Phase 1 trial for AP24534 signals an

important advance in the development of our growing portfolio of oncology

product candidates, " said Pierre Dodion, M.D., senior vice president and chief

medical officer ARIAD. " Discovered by ARIAD scientists, AP24534 has been shown

to selectively block a series of well-validated cancer targets known to play

critical roles in the pathogenesis of several hematological cancers and solid

tumors. Especially in patients with the drug-resistant forms of CML, where the

genetic basis for the disease can be readily measured in individual patients, we

expect this trial to provide insights into the potential therapeutic effects of

AP24534 early in its clinical development.

" ARIAD's second oncology product candidate, AP24534, is an investigational oral

multi-targeted tyrosine kinase inhibitor that has broad potential applications

in cancer. In preclinical studies, AP24534 has demonstrated potent inhibition of

kinase targets associated with drug-resistant chronic myeloid leukemia and acute

myeloid leukemia, as well as angiogenesis in multiple solid tumors. AP24534 has

completed extensive preclinical studies, including safety assessment studies,

which indicate that the drug candidate should be well tolerated at anticipated

therapeutic dose levels in cancer patients. In addition to the clinical study in

hematological malignancies described above, further clinical development in

patients with solid tumors is expected to begin later in 2008. Additional

information about the ongoing clinical trial can be found at

http://clinicaltrials.gov/ct2/show/NCT00660920?term=AP24534 & rank=1.

" This multi-center, sequential dose-escalation trial will evaluate up to fifty

patients with refractory hematological cancers, each of whom will receive a

fixed oral dose of AP24534 once daily without interruption. Patients will remain

on treatment until they reach predetermined endpoints. "

By the way, I put in a call to them to see if they would share some information

with me and asked when and where the trials would be held. I can only speculate

as to what they will say, they are all such closely guarded secrets. Will let

you know if they return my call.

Blessings & peace of mind,

Lottie